MedTrace Logo

Study of SGR-3515 In Participants With Advanced Solid Tumors.

NCT06463340 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-08-01

No results posted yet for this study

Summary

The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SGR-3515

SGR-3515 will be administered orally with an intermittent schedule.

Sponsors & Collaborators

  • Schrödinger, Inc.

    lead INDUSTRY

Principal Investigators

  • Margaret Dugan, MD · CMO/Study Physician

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-18
Primary Completion
2026-10-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06463340 on ClinicalTrials.gov